Huahao Zhongtian Pharmaceutical-B (02563.HK): First patient dosed in Phase III clinical trial of Utidelone capsules for HER2-negative advanced breast cancer

Zhitong Finance APP News, Biostar Pharmaceuticals-B (02563.HK) announced that the Company's core pipeline Utidelone Capsules (UTD2) for the treatment of human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer Phase III clinical study (BG02-2601) has successfully achieved first patient dosing, marking the official launch of the world's first pivotal registration clinical trial of an oral solid microtubule stabilizer.